Treatment of disorders caused by nonsense [premature stop codon] mutations. Overrides nonsense stop translation signals to yield full-length proteins; may prove useful in treating cystic fibrosis and Duchenne muscular dystrophy.
Mode of Action:
Products currently covered by valid US Patents are offered for R&D use in accordance with 35 USC 271(e)+A13(1). Any patent infringement and resulting liability is solely at buyer risk.
API’s From Quality Manufacturers:
Cost effective materials based on specific requirements
Small quantities for initial research and larger development quantities towards product commercialization
Technical packages, letters of access to filed DMFs